Home › NDC Lookup › RxCUI directory › RxCUI 311918

Naratriptan 1 MG Oral Tablet — RxCUI 311918

RxNorm drug concept · Semantic clinical drug
RxCUI 311918 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 10 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI311918
Official nameNaratriptan 1 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnaratriptan (as naratriptan hydrochloride) 1 MG Oral Tablet
FDA products mapped6
Package NDCs mapped10
Reported Medicaid activity (SDUD)51,801 prescriptions · 48 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Naratriptan: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Naratriptan is specifically designed to treat migraine attacks — it targets the biological processes that cause migraine pain, including blood vessel changes and the release of pai...
  • What exactly is naratriptan for, and how is it different from everyday pain relievers?
  • You can take naratriptan at the onset of a migraine. There's no need to wait until the pain becomes severe — in fact, taking it early during an attack tends to work better. If your...
  • When should I take it during a migraine — right away, or should I wait to see if it gets bad?
📖 Read our full Naratriptan guide →

🕸️ Concept Web — How Naratriptan 1 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Naratriptan 1 MG Oral Tablet RxCUI 311918

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Naratriptan 141366
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Naratriptan Oral Tablet 373010
    • Naratriptan Oral Product 1158390
    • Naratriptan Pill 1158391
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Naratriptan 1 MG 330059

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Naratriptan 1 MG SCDC · 330059
  • Naratriptan Oral Tablet SCDF · 373010
  • Naratriptan Oral Product SCDG · 1158390
  • Naratriptan Pill SCDG · 1158391

📦 FDA Products & Package NDCs

6 products · 10 package NDCs
10 package NDCs map to RxCUI 311918 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00054-0278-03 9 TABLET in 1 BOTTLE (0054-0278-03) Naratriptan Hikma Pharmaceuticals USA Inc. 2010-10-07
00054-0279-03 9 TABLET in 1 BOTTLE (0054-0279-03) Naratriptan Hikma Pharmaceuticals USA Inc. 2010-10-07
23155-0054-03 30 TABLET in 1 BOTTLE (23155-054-03) naratriptan Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2011-03-15
23155-0054-05 500 TABLET in 1 BOTTLE (23155-054-05) naratriptan Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2011-03-15
23155-0054-19 9 TABLET in 1 BLISTER PACK (23155-054-19) naratriptan Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2011-03-15
23155-0055-03 30 TABLET in 1 BOTTLE (23155-055-03) naratriptan Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2011-03-15
23155-0055-05 500 TABLET in 1 BOTTLE (23155-055-05) naratriptan Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2011-03-15
23155-0055-19 9 TABLET in 1 BLISTER PACK (23155-055-19) naratriptan Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2011-03-15
69452-0340-72 1 BLISTER PACK in 1 CARTON (69452-340-72) / 9 TABLET, FILM... Naratriptan Bionpharma Inc. 2022-04-11
69452-0341-72 1 BLISTER PACK in 1 CARTON (69452-341-72) / 9 TABLET, FILM... Naratriptan Bionpharma Inc. 2022-04-11
Observed labelers: Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (6) · Bionpharma Inc. (2) · Hikma Pharmaceuticals USA Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.